Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The archaelysin family metallopeptidase 2 pseudogene (ENSG00000204399) is a segment of human DNA that closely resembles the sequence of archaelysin family metallopeptidase 2 (AMZ2) but has lost the ability to produce a functional protein due to mutations or truncations. Pseudogenes such as this typically arise by gene duplication or retrotransposition and eventually accumulate mutations that render them nonfunctional[3][4]. These genetic elements do not encode active proteins nor serve as direct drug targets, but may contribute to genomic evolution or, in rare cases, regulatory functions. For archaelysin family metallopeptidase 2 pseudogene, there is no evidence of biological, therapeutic, or diagnostic significance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Archaelysin family metallopeptidase 2 pseudogene (AMZ2 pseudogene).